The GLP is committed to full transparency. Download and review our 2019 Annual Report

Bayer could face over 45,000 glyphosate-cancer cases as settlement talks continue

| | October 17, 2019
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Bayer expects the number of claims in the United States related to Roundup herbicide to have surged in the third quarter, as the German drugs and pesticides maker tries to reach a settlement after earlier court rulings against it.

“With the substantial increase in plaintiff advertising [in 2019], we expect to see a significant surge in the number of plaintiff filings over the third quarter,” the company said in a written statement.

Analysts at JP Morgan, citing an analysis of Missouri court data, said in an Oct. 9 research note that the total number of glyphosate cases could rise to more than 45,000.

Related article:  In GMO debate, what's worse? Biased scientists or uncritical media?

Bayer, which acquired Roundup and other glyphosate-based weed killers as part of its $63 billion takeover of Monsanto [in 2018], faces potentially heavy litigation costs as plaintiffs claim Roundup causes cancer, something Bayer disputes.

Read full, original article: Bayer expects significant surge in number of U.S. glyphosate cases

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend